ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2016
Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Economic Burden of Community-Acquired Antibiotic-Resistant Urinary Tract Infections: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2024Pooled it
- Prevalence and outcome of bloodstream infections due to third-generation cephalosporin-resistant Enterobacteriaceae in sub-Saharan Africa: a systematic review.The Journal of antimicrobial chemotherapy · 2020Pooled it
- Mortality outcomes and economic burden of antimicrobial-resistant bacterial bloodstream infections in a Nigerian tertiary hospital.BMC microbiology · 2026Article
- Extraintestinal Invasive Escherichia coli Infections in the US.JAMA network open · 2026Article
- Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002-2022.Infectious diseases and therapy · 2026Article
- ZoonoticmBio · 2025Article
- A qualitative burden of disease study in patients with invasive Escherichia coli disease aged ≥ 60 years in the United States.BMC infectious diseases · 2025Article
- Clinical Predictors ofAntibiotics (Basel, Switzerland) · 2025Article
- Incidence, case-fatality rates and risk factors of bloodstream infections caused byEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention.Nature reviews. Microbiology · 2025Review
- Epidemiology of invasiveEpidemiology and infection · 2025Article
- Clinical epidemiological characteristics and antibiotic sensitivity of Escherichia coli urinary tract infection.PloS one · 2025Article
- Predicting future hospital antimicrobial resistance prevalence using machine learning.Communications medicine · 2024Article
- A Rare Case and Literature Review of Pyelo-Hepatic Abscess in an Immunocompetent Patient: When Effective Source Control and Targeted Antimicrobial Therapy Might Not Be Enough.Microorganisms · 2024Article
- Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning.BMC infectious diseases · 2024Article
- A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.NPJ vaccines · 2024Article
- Observational
- Phenotypic and genotypic evaluation of aminoglycoside resistance inIranian journal of microbiology · 2024Article
- Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
- Sex-related immunity: could Toll-like receptors be the answer in acute inflammatory response?Frontiers in immunology · 2024Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We determined the incidence, risk factors and antimicrobial susceptibility associated with Escherichia coli bacteraemia in England over a 24 month period. Case data were obtained from the national mandatory surveillance database, with susceptibility data linked from LabBase2, a voluntary national microbiology database. Between April 2012 and March 2014, 66,512 E. coli bacteraemia cases were reported. Disease incidence increased by 6% from 60.4 per 100,000 population in 2012-13 to 63.5 per 100,000 population in 2013-14 (p < 0.0001). Rates of E. coli bacteraemia varied with patient age and sex, with 70.5% (46,883/66,512) of cases seen in patients aged ≥ 65 years and 52.4% (33,969/64,846) of cases in females. The most common underlying cause of bacteraemia was infection of the genital/urinary tract (41.1%; 27,328/66,512), of which 98.4% (26,891/27,328) were urinary tract infections (UTIs). The majority of cases (76.1%; 50,617/66,512) had positive blood cultures before or within two days of admission and were classified as community onset cases, however 15.7% (10,468/66,512) occurred in patients who had been hospitalised for over a week. Non-susceptibility to ciprofloxacin, third-generation cephalosporins, piperacillin-tazobactam, gentamicin and carbapenems were 18.4% (8,439/45,829), 10.4% (4,256/40,734), 10.2% (4,694/46,186), 9.7% (4,770/49,114) and 0.2% (91/42,986), respectively. Antibiotic non-susceptibility was higher in hospital-onset cases than for those presenting from the community (e.g. ciprofloxacin non-susceptibility was 22.1% (2,234/10,105) for hospital-onset vs 17.4% (5,920/34,069) for community-onset cases). Interventions to reduce the incidence of E. coli bacteraemia will have to target the community setting and UTIs if substantial reductions are to be realised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.